A Phase 1, Open-label, Randomized, PK and Safety Study To Assess Bronchopulmonary Disposition of Intravenous TP-6076 in Healthy Men and Women
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs TP 6076 (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Acronyms BAL
- Sponsors Tetraphase Pharmaceuticals
- 10 Sep 2019 Planned End Date changed from 1 May 2019 to 28 Feb 2020.
- 10 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 08 May 2019 According to a Tetraphase Pharmaceuticals media release, the study is expected to complete in 2H 2019.